{"filing":{"accession_number":"0001213900-26-083984","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"ea0300019-6k_neuro.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026083984/ea0300019-6k_neuro.htm"},"events":[{"id":22405,"run_id":20268,"accession_number":"0001213900-26-083984","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The 6-K discloses an amendment to a Capital on Demand™ Sales Agreement with JonesTrading, updating the registration statement reference to Form F-3 (File No. 333-293060) effective July 31, 2026, permitting the Company to offer and sell up to $3,789,822 in ordinary shares. This is a dilutive equity issuance arrangement under an ATM (at-the-market) offering program, a material capital-raising activity typical of small-cap biotech firms. The Company has already sold 6,762,825 shares for ~$6.7 million under the prior agreement, demonstrating active use of the facility.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":22334,"accession_number":"0001213900-26-083984","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The 6-K discloses an amendment to a Capital on Demand™ Sales Agreement with JonesTrading, updating the registration statement reference to Form F-3 (File No. 333-293060) effective July 31, 2026, permitting the Company to offer and sell up to $3,789,822 in ordinary shares. This is a dilutive equity issuance arrangement under an ATM (at-the-market) offering program, a material capital-raising activity typical of small-cap biotech firms. The Company has already sold 6,762,825 shares for ~$6.7 million under the prior agreement, demonstrating active use of the facility.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:13:47.685547+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-07-31"}]}